Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Osiris
 More »

  • People in the News
    Hans Klingemann, M.D., Ph.D. Conkwest hired Hans Klingemann, M.D., Ph.D. , as CMO and CSO. Dr. Klingemann is a member of the board for Osiris Therapeutics. Previously, he was ...
    4-15-2013
  • Medicine: Getting Personal
    ... Cell therapy and cell-based regenerative medicine raised more than $1 billion in 2012, based on all forms of funding. 3. Approval of Osiris Therapeutics' Prochymal stem cell ...
    3-15-2013
  • Gene Therapy Briefs
    The guideline addresses requirements for the genetic modification of the target cell population and for the transduced cell product resulting from the manufacturing process. Osiris ...
    7-1-2012
  • Osiris Wins Race to Market a Stem Cell Product with Canadian...
    Osiris Therapeutics' adult stem cell therapy Prochymal® received approval from Health ... The decision gives Osiris the distinction of being the first company to win full marketing ...
    5-18-2012
  • Regenerative Medicine Field Takes Shape
    ... Osiris began its mesenchymal stem cell program in 1992 and won approval to begin Phase III ... Since then, Osiris has expanded its stem cell program to include anti-inflammatory ...
    7-1-2011
  • Japan Disaster Renews Interest in Antiradiation Drug Development
    ... Therapeutics with $153 million over five years for CLT-008, Derma Sciences with $14 million over five years for DSC127, and Osiris Therapeutics with $224.7 million for Prochymal. ...
    4-20-2011
  • Innovations Continue to Drive Market Gains
    ... McCusker believes the companies to watch are Geron, Cytori, Biotime, Pluristem, and Osiris... Revenues are expected to be in the $12-$15 million range in 2011. Osiris Therapeutics' ...
    4-1-2011
  • Regenerative Medicine Stays Its Course
    ... Osteocel In 2005, Osiris Therapeutics (www.osiristx.com) began distribution of its ... completed its acquisition of the Osteocel biologics business from Osiris Therapeutics. ...
    3-1-2011
  • 2010 in Review: Biotechnology Highlights
    ... the first patient in October 2010. Adult stem cell therapies have had better luck in the clinic, with Osiris and TCA Cellular Therapy moving their products into Phase III testing. ...
    12-30-2010
  • Is the Progression of Adult Stem Cell Therapies into the Clinic...
    Osiris is a contender to be the first to obtain positive Phase III results for an adult ... In February, though, Osiris reported that it showed potential when used as a rescue ...
    5-26-2010
  • Osiris' Race to Market an FDA-Approved Stem Cell Product
    Closest to an off the shelf stem cell product is Osiris Therapeutics' Prochymal, a human ... failures in that indication during 2009. Osiris continues to assert, though, that MSCs ...
    5-17-2010
  • Osiris Restarts Phase III Prochymal Trial in Crohn Disease Following...
    Osiris Therapeutics has restarted patient enrollment into a Phase III trial (Protocol 603) ... This trial has been discontinued to remove the potential for bias, Osiris notes. "We will ...
    5-6-2010
  • Benefits of Osiris' Mesenchymal Stem Cell Therapy Confirmed in...
    Osiris Therapeutics' stem cell product Prochymal showed significant benefits as a ... is the first stem cell product to receive FDA expanded access approval, Osiris points out. ...
    2-24-2010
  • Stem Cell Possibilities Energize the Market
    are many companies that are active in the development of stem cell products, including Osiris Therapeutics, NuVasive, Aastrom Biosciences, BrainStorm Cell Therapeutics, Genzyme, ...
    7-1-2009
  • Lonza Expands Cell Therapy Production into Asia
    Lonza to Help Advance Biologics (July 11, 2008) Lonza Reports Manufacturing Deal with Osiris and Facility Constructions (July 1, 2008) Lonza Takes Over Amaxa to Pad Cell-Discovery ...
    5-15-2009

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll